News ASCO: TIGIT returns with Roche, Gilead data A year ago, enthusiasm for a new generation of cancer immunotherapies targeting TIGIT started to wane, after Roche’s tiragolumab was hit by two
News FDA clears Viridian's Tepezza rival for thyroid eye disease Viridian has fired a shot across Amgen's bows with the FDA approval of Tepezza rival Lumvoa in thyroid eye disease, a $2bn market.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
